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Abstract
Purpose—This study assessed whether Myristoylated Alanine Rich C-Kinase Substrate
(MARCKS) can regulate glioblastoma (GBM) growth, radiation sensitivity and clinical outcome.
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Experimental Design—MARCKS protein levels were analyzed in five GBM explant cell lines
and eight patient-derived xenograft tumors by immunoblot, and these levels were correlated to
proliferation rates and intracranial growth rates, respectively. Manipulation of MARCKS protein
levels was assessed by lentiviral-mediated shRNA knockdown in the U251 cell line and
MARCKS over-expression in the U87 cell line. The effect of manipulation of MARCKS on
proliferation, radiation sensitivity and senescence was assessed. MARCKS gene expression was
correlated with survival outcomes in the Repository of Molecular Brain Neoplasia Data
(REMBRANDT) Database and The Cancer Genome Atlas (TCGA).
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Results—MARCKS protein expression was inversely correlated with GBM proliferation and
intracranial xenograft growth rates. Genetic silencing of MARCKS promoted GBM proliferation
and radiation resistance, while MARCKS overexpression greatly reduced GBM growth potential
and induced senescence. We found MARCKS gene expression to be directly correlated with
survival in both the REMBRANDT and TCGA databases. Specifically, patients with high
MARCKS expressing tumors of the Proneural molecular subtype had significantly increased
survival rates. This effect was most pronounced in tumors with unmethylated O6-methylguanine
DNA methyltransferase (MGMT) promoters, a traditionally poor prognostic factor.
Conclusions—MARCKS levels impact GBM growth and radiation sensitivity. High MARCKS
expressing GBM tumors are associated with improved survival, particularly with unmethylated
MGMT promoters. These findings suggest the use of MARCKS as a novel target and biomarker
for prognosis in the Proneural subtype of GBM.

INTRODUCTION
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Glioblastoma multiforme (GBM) represents the most common and deadly form of glioma
(1). The current mainstay of treatment for GBM is surgical resection followed by radiation
with concurrent and adjuvant chemotherapy with an alkylating agent. Indeed, the most
significant developments in recent years were the improvement in survival with the addition
of temozolomide to treatment regimens (2), and the recognition that the O-6-methylguanineDNA methyltransferase (MGMT), a DNA repair protein encoded by the MGMT gene, is a
key prognostic variable in glioma. The MGMT protein can effectively reverse the
predominant DNA lesion produced by temozolomide chemotherapy, that of DNA
methylation at the O-6 position of guanine (3). MGMT protein expression can be regulated
through epigenetic silencing of the MGMT promoter through methylation. Therefore,
methylated MGMT (often called hypermethylated MGMT) results in a silencing of MGMT
transcription. Tumors with methylated MGMT (~33–45% of GBM) have a better prognosis
overall and predict for improved response to temozolomide and radiation therapy (3, 4). The
improvement in median survival was modest, however, from 12.1 to 14.6 months postdiagnosis (2). Conversely, unmethylated MGMT tumors have an intact MGMT DNA repair
mechanism that yields poorer survival and earlier treatment failure. There are currently no
proven alternative treatment options for those patients with un-methylated MGMT promoter
status.
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The MGMT DNA repair mechanism is merely one of many processes that contribute to poor
survival in GBM. It is well known that several different mutations in oncogenes and loss of
tumor suppressors may contribute to the pathogenesis of GBM, and these aberrations differ
from patient to patient. This would suggest that effective treatment regimens for GBM
should be tailored toward the particular pathogenesis of that patient’s neoplasm. Over the
past several years, there have been many attempts to generate molecular profiles to better
understand GBM and the prognostic factors that influence survival and response to therapy.
Resources such as the Repository of Molecular Brain Neoplasia Data (REMBRANDT)
database and The Cancer Genome Atlas (TCGA) Research Network have provided insight
into the pathogenesis of GBM through allowing researchers to correlate gene expression
with clinical outcome. Recently, genomic analyses of TCGA GBM samples lead to the
identification of molecular subtypes, namely Classical, Mesenchymal, Proneural, and
Neural. Indeed, abnormalities in several oncogenes and tumor suppressors were identified
that are characteristic of each subtype (5, 6). Moreover, treatment efficacy differs among the
subtypes, indicating that future clinical approaches will depend on subtype specificity (6).
One of the most common genetic alterations observed in approximately 90% of GBM is loss
of heterozygosity (LOH) of chromosome 10q (7). This alteration often occurs in conjunction
with mutation of the tumor suppressor gene Phosphatase and Tensin Homolog (PTEN) in up
Clin Cancer Res. Author manuscript; available in PMC 2013 August 29.
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to 60% of GBMs with LOH (8, 9). PTEN executes its tumor suppressor function by
antagonizing signaling through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
Activation of the PI3K/Akt pathway begins when the phospholipid, phosphatidylinositol
(4,5) bisphosphate (PIP2) is phosphorylated by PI3K to phosphatidylinositol (3,4,5)triphosphate (PIP3). PIP3 can then recruit the kinase Akt to the plasma membrane where it
is phosphorylated and activated leading to changes in migration, invasion, angiogenesis,
survival and proliferation. PIP3 can also be converted back to PIP2 by PTEN. Therefore,
mutations or deletions of PTEN in gliomas lead to an over-activation of the Akt pathway
and have been associated with a worse clinical outcome (10–13). This would indicate that
the availability of the precursor phospholipid PIP2 is a critical factor for modulating
activation of Akt and potentially, clinical outcome.

NIH-PA Author Manuscript

MARCKS is a protein that is capable of regulating PIP2 availability by sequestration via an
electrostatic mechanism. MARCKS was identified over 20 years ago as a major protein
substrate for protein kinase C (PKC) in brain synaptosomes (14). Since then, its major role
has been defined as an integrator of PKC and Calmodulin signals into control of the actin
cytoskeleton (15). It performs this function with its poly-basic effector domain that crosslinks actin filaments into bundles and sequesters PIP2 with favorable stoichiometry via an
electrostatic mechanism (16, 17). Phosphorylation of the effector domain by PKC or binding
by Ca2+-Calmodulin leads to a local release of PIP2 and actin bundles; resulting in
alterations in the actin cytoskeleton. This is the mechanism by which MARCKS controls
cellular structural changes such as the extension of growth cones in neurons and the
promotion of chemotaxis in neutrophils (18, 19). MARCKS has also been implicated in the
pathogenesis of various malignancies. A particular mutation which truncates the protein
within the effector domain is common in small intestinal adenocarcinomas (20). Levels of
MARCKS were found to be inversely correlated with increased proliferation in melanoma
cells, suggesting that MARCKS may function as a “tumor suppressor” (21). Interestingly, a
recent study on MARCKS in GBM implicated this protein as a mediator of attachment and
invasion, suggesting that higher levels of MARCKS would lead to a more aggressive disease
(22). It is clear that the function of this protein in the pathogenesis of malignancy is multifaceted and complex.
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Due to the MARCKS protein’s ability to sequester PIP2, we hypothesized that MARCKS
may be able to regulate growth and radiation sensitivity in GBM through regulation of the
PI3K/Akt pathway. GBM cell lines and tumors with higher levels of MARCKS would have
reduced availability of PIP2 for conversion to PIP3 and thus reduced activation of the PI3K/
Akt pathway. This would lead to reduced growth rates and resistance to radiation; which
could in turn lead to improved clinical outcomes. We investigated this in several established
GBM cell lines as well as a patient-derived tumor xenograft mouse model. We confirmed
the effect of MARCKS in the regulation of proliferation and radiation sensitivity with
molecular manipulation and also identified a novel role in the regulation of senescence. To
more closely evaluate the MARCKS protein in a clinical context, we then correlated
MARCKS gene expression with molecular subtypes and clinical outcome. We found
MARCKS expression to be particularly protective in the Proneural subtype of GBM,
indicating that this protein may be a novel biomarker and therapeutic strategy for these
patients.

MATERIALS AND METHODS
Xenograft passaging and processing
All animal studies were carried out in accordance with the policies set by the UAB IACUC.
Dr. C. David James (UCSF, San Francisco, CA) and Dr. Jann Sarkaria (Mayo Clinic,
Rochester, MN) have developed several partially characterized human glioblastoma
Clin Cancer Res. Author manuscript; available in PMC 2013 August 29.
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xenograft lines through serial passage within athymic nude mice (23–25). Eight of these
human glioblastoma xenograft lines were provided to Dr. Gillespie (UAB) and have been
used for this study. Athymic nu/nu mice were obtained from National Cancer Institute
Mouse Repository (NCI-Frederick, MD). The following primary glioblastoma xenograft
lines were used for this study: GBM 6, GBM 10, GBM 12, GBM 14, GBM 15, GBM 22,
GBM 39, and GBM 59 (23–25). Tumors xenografts were serially passaged in the mice
(flanks) by harvesting and mechanically disaggregating the cells prior to injection as has
been described before (23–25). Gross tumor is macrodissected from normal tissue and snap
frozen for kinomic profiling and immunoblotting as detailed below. Intracranial tumor
growth was determined by measuring the time from intracranial implantation to the day the
mice begin to show neurological impairment.
Immunoblotting

NIH-PA Author Manuscript

Immunoblotting was performed by standard protocols with the following primary
antibodies: rabbit anti-MARCKS, Epitomics, catalog # 1944-1; rabbit anti-MARCKS
pS158/162, Epitomics, catalog # 2156-1; rabbit anti-Akt, Cell Signaling, catalog # 4691;
rabbit anti-Akt pSer473, Cell Signaling, catalog # 4060S; rabbit anti-phospho DNA-PKcs
T2609, Genetex, catalog #GTX-24194; rabbit anti-phospho H2AX Ser139, Millipore,
catalog #MI-07-164; rabbit anti-LCB3, Novus Biologicals, catalog #NB600-1384; rabbit
anti-Caspase 3, Cell Signaling, catalog #9662S; rabbit anti-GAPDH, Santa Cruz, catalog #
sc-25778; mouse anti-αTubulin, Santa Cruz, catalog #sc-5286. A detailed description of the
protocol is contained in the Supplementary Methods.
Plasmid constructs
A set of five MARCKS shRNA lentiviral transfer vector plasmids (catalog # RHS4533NM_002356) and an empty vector control plasmid (catalog # RHS4080) were obtained from
Thermo Biosystems. The psPAX2 packaging plasmid (Addgene plasmid 12260) and
pCMV-VSV-G envelope plasmid (Addgene plasmid 8454) were obtained from Addgene
(26). Detailed description of the construction of the pLenti4-MARCKS and pLenti4-DELTA
plasmids is contained in the Supplementary Methods.
Lentiviral vector production
Lentivirus was generated by co-transfection of 293FT cells with pCMV-VSVG, psPAX2,
and the appropriate lentiviral transfer vector with Lipofectamine. A detailed description of
the production of lentivirus is contained in the Supplementary Methods.
Cell culture and stable line selection
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U87, U251, U373, U118, D54 and D32 malignant glioma cell lines (American Type Culture
Collection) and 293FT human embryonic kidney cells (Invitrogen) were cultured in DMEM
with 10% FBS and 1% Pen-Strep at 37°C in 5% CO2. A detailed description of stable cell
line selection is contained in the Supplementary Methods.
Proliferation assay
2×103 cells were seeded in 96-well plates in 100μL of media. Cells were allowed to grow
for 5 days and were then harvested with the ATPlite Luminescence Assay System (catalog #
6016949, Perkin-Elmer) or WST-1 assay System (Calbiochem) per manufacturer’s
instructions. Fluorescence was measured on a Synergy H1 Hybrid plate reader (Biotek) and
absorbance was read on a Vmax Kinetic Microplate Reader (Molecular Devices). All
measurements were performed in quadruplicate.

Clin Cancer Res. Author manuscript; available in PMC 2013 August 29.
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U251 control and MARCKS knockdown cells grown to 80% confluency were trypsinized,
counted with a hematocytometer, and serially diluted to defined concentrations. Three
different defined numbers of cells were plated per dose of radiation in duplicate. Eight hours
later, the cells were treated with 0, 3, 5, or 8 Gy radiation. Fourteen days later, cells were
fixed and stained with 6.0% glutaraldehyde and 0.5% crystal violet. Colonies were counted
in quadruplicate for each condition and a surviving fraction (S.F.) was calculated by using
the equation (number of colonies formed/number of cells plated)/(number of colonies for
sham irradiated group/number of cells plated). The results were then plotted as mean and
standard error of the mean in a semi-logarithmic format using Microsoft Excel software.
Dose enhancement ratio (DER) is calculated as the dose (Gy) for control divided by the dose
for MARCKS knockdown treated cells (normalized for plating efficiency at 0 Gy) for which
a S.F.=0.2 is achieved.
Clinical data
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Clinical and gene expression data was obtained from the REMBRANDT database and
TCGA Project. Gene expression values from the Affymetrix U133 Plus 2.0 Array Platform
for MARCKS were downloaded for all glioma samples in the REMBRANDT database
through the Advanced Search function. The clinical data was downloaded for these samples
in BRB format through the Download function. For TCGA analysis, we used 192 out of the
202 patients that did not have prior glioma. Gene expression data from three separate
microarray platforms was summarized by gene across three different microarray platforms
using a method described elsewhere (6). The gene-summarized gene expression values are
contained in the supplementary materials in (Verhaak et al., 2010) (6) for 11,861 genes from
the TCGA samples. Basic sample characteristics such as counts by subtype, MGMT status,
etc., are given elsewhere (6). A detailed description of the survival analysis is included in
the Supplementary Methods.
Statistical analysis for in vitro data
The in vitro data were analyzed via analysis of variance (ANOVA) followed by a
Bonferroni post-test using GraphPad Prism version 4.02 (GraphPad Software, San Diego,
CA). Data is presented as average +/− standard error of mean.

RESULTS
MARCKS Regulates GBM Growth Rates in Cell Lines and in Human Xenografts

NIH-PA Author Manuscript

Previous studies have implicated a potential tumor suppressor role for the MARCKS protein
(21). We thus hypothesized that GBM cell lines with higher levels of the MARCKS protein
would have slower growth rates. To test our hypothesis, we measured MARCKS protein
expression (normalized to GAPDH) in several well characterized immortalized GBM cell
lines (Fig. 1A) demonstrating a spectrum of proliferation rates (Supplementary Fig. S1). We
found variable MARCKS expression levels across these cell lines and that MARCKS levels
inversely correlated (R2= 0.4847) with GBM cell proliferation (Fig. 1B). Despite the
extensive characterization of these cell lines, however, it has been realized that they harbor
genetic alterations relative to the original tumor (27). We thus performed a similar analysis
with a more clinically relevant xenograft model.
The genetic makeup of the original tumor can be effectively preserved if the cells are
maintained as xenolines in immunocompromised mice after direct implantation of patient
tumor tissue (28). Human-derived GBM xenografts have been established by direct
implantation of patient tumor tissue within immunocompromised mice and are serially
passaged within these mice as xenograft lines. It has been shown that these xenografts do
Clin Cancer Res. Author manuscript; available in PMC 2013 August 29.
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not demonstrate substantial alteration of genetic changes as compared to the original tumor
(29). For this reason, these xenografts exhibit a wide range of intracranial growth rates and
common genetic alterations that are seen in GBM (Supplementary Table 1). We performed
similar measurements in the GBM xenografts (Fig. 1C) and correlated those levels with the
average time of intracranial tumor growth for each tumor xenograft. This represents the
average time from intracranial implantation to the time of passage (when mice demonstrate
neurological decline) and thus is an inverse surrogate measure for their tumor proliferation
rates (Supplementary Table 1). As in the GBM cell lines, there was an inverse correlation
between the tumor xenograft intracranial growth rates and MARCKS expression levels (Fig.
1D; R2=0.4466), suggesting that MARCKS is an important regulator of GBM growth.
MARCKS Silencing Leads to Increased Growth Rates and Radiation Resistance
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Our xenograft and cell culture data implicated MARCKS as a potential regulator of GBM
growth. Therefore, we manipulated MARCKS expression in GBM cell lines to determine
whether MARCKS directly affected GBM growth. We investigated MARCKS gene
silencing using lentiviral-mediated MARCKS shRNA knockdown in U251 cells (high basal
MARCKS expression). A control cell line was generated utilizing an empty vector control
lentivirus. A stable 40% knockdown of the MARCKS protein in U251 cells (Fig. 2A)
demonstrated a 26% increase in proliferation rate (p<0.01) (Fig. 2B). Because MARCKS
can sequester PIP2, we suspected that knockdown of MARCKS would be associated with
increased signaling through PI3K/Akt due to increased availability of PIP2 for conversion to
PIP3 by PI3K. Akt is activated by phosphorylation of serine 473 after recruitment to the
membrane by PIP3. We thus assessed our MARCKS knockdown for activation of Akt by
immunoblotting for phosphoserine-473. Decreases in U251 MARCKS levels produced
increased activation of Akt compared to control (Fig. 2A). To demonstrate that signaling
through the PI3K/Akt pathway was responsible for these increases in proliferation we
treated the MARCKS knockdown cells with the PI3K inhibitor LY294002 at 10μM.
Treatment with LY294002 led to an 87% decreased activation of Akt as assessed by
densitometry (Supplementary Fig. S2A) and subsequent decreases in proliferation
(Supplementary Fig. S2B)(p = 0.0287). This suggests that decreased levels of MARCKS
promote increased proliferation through enhanced signaling through PI3K/Akt.
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Increased signaling through Akt has been implicated in therapeutic resistance due to
increased DNA repair and decreased apoptosis (30, 31). We thus hypothesized that
MARCKS knockdown would lead to increased radiation resistance. We assessed the
radiation sensitivity of our knockdown cell line by a clonogenic assay and found a
significant increase in radiation resistance with lower levels of MARCKS compared to
control (Dose enhancement ratio = 0.75; 3 Gy p<0.0001, 5 Gy p=0.0002, 8 Gy p<0.0001)
(Fig. 2C and Supplementary Fig. S2C). Radiation induces cell death by multiple
mechanisms such as apoptosis, autophagy, mitotic catastrophe, and senescence. It is thought
that cell death occurs due to failure of the cell to adequately repair the DNA damage induced
by irradiation. Activation of PI3K/Akt has been demonstrated to lead to decreased apoptosis
as well as increased DNA repair by a non-homologous end joining (NHEJ) mechanism (32).
We therefore investigated how knockdown of the MARCKS protein might affect these
forms of cell death.
To investigate the mechanism of DNA repair, we quantified DNA double strand breaks
(DSBs) over time after radiation. The DSB is the most lethal lesion inflicted by radiation.
Upon sensing a DSB, the cell will phosphorylate histone H2A on serine 139 (γH2AX).
Thus, staining for γH2AX foci as a marker for DNA DSB over time is a common method of
investigating the rate of DNA repair. We noted a significantly decreased presence of DNA
DSBs over time after radiation in our knockdown cell line (p<0.001 at 30 minutes, 1 hour, 4
hours and 8 hours)(Fig. 3A). To demonstrate that this effect could be due to increased DNA
Clin Cancer Res. Author manuscript; available in PMC 2013 August 29.
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repair by NHEJ, we immunoblotted for phosphorylated DNA-dependent protein kinase,
catalytic subunit (DNA-PKcs) in our control and knockdown cell lines after irradiation. We
found that MARCKS knockdown lead to a 4-fold increase in peak DNA-PKcs activation
after 8 Gy as assessed by densitometry (Fig 3B). Treatment of the MARCKS knockdown
cell line with LY294002 at 10μM for 1 hour prior to radiation abrogated activation of DNAPKcs, suggesting that this increase in DNA repair is mediated through PI3K/Akt signaling
(Supplementary Fig. S3A). This increased DNA repair mechanism would suggest that
manipulation of MARCKS levels would alter the various forms of cell death induced after
irradiation. We therefore assessed the effect of MARCKS knockdown on cell cycle, mitotic
catastrophe, autophagy, senescence and apoptosis. Cell cycle analysis was performed in the
control and knockdown cell line after 8 Gy. We found no difference in the basal cell cycle
distribution, however; knockdown of the MARCKS protein lead to a more rapid recovery
toward the basal cell cycle distribution at 24 hours after 8 Gy (Fig. 3C and Supplementary
Fig. S3B, C). This is consistent with more rapid DNA repair and recovery from cell cycle
arrest. Mitotic catastrophe was assessed after 8 Gy at 24, 48, and 72 hours by DAPI staining
and quantification of multi-nucleated cells (Supplementary Fig. S4A). We found a decrease
in mitotic catastrophe with MARCKS knockdown at 48 hours compared to control
(p=0.0242), but no difference at 24 or 72 hours (Fig. 4A). Senescence was assessed by
staining for senescence associated β-galactosidase (SA-β-gal), a widely used biomarker of
senescent cells (33). We did not detect senescence in either the control or MARCKS
knockdown cell line after 8 Gy up to 72 hours (data not shown). Autophagy was quantified
by immunoblotting for cleavage of the LC3-I protein to LC3-II, which is associated with
completed autophagasomes and is often used as a marker for autophagy. We found a 2.95fold increase (normalized to α-Tubulin) in LC3-II with knockdown of MARCKS (Fig. 4B),
consistent with previous reports that the PI3K/Akt pathway negatively regulates autophagy
(34). We assessed apoptosis by immunoblotting for cleaved caspase 3 and quantification of
pyknotic nuclei with DAPI stain after 8 Gy treatment. We found an increase in cleaved
caspase 3 at 24 hours (Fig. 4C), as well as an increased presence of pyknotic nuclei at 24, 48
and 72 hours in the control cell line (Fig. 4D and Supplementary Fig. S4A) (p<0.05). These
results suggest that knockdown of MARCKS leads to increased resistance to radiation by
increased DNA repair. This causes a more rapid recovery from cell cycle arrest, decreased
apoptosis, and decreased mitotic catastrophe.
MARCKS Over-expression Leads to Decreased Growth Rates and Senescence
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Since a reduction in MARCKS levels led to increased growth and resistance to radiation, we
hypothesized that MARCKS overexpression would lead to decreased growth and increased
sensitivity to radiation. MARCKS overexpression was achieved in U87 GBM cells (low
basal MARCKS expression) using lentiviral infection, with an empty vector lentivirus as a
control. Expectedly, 6.3-fold over-expression of the MARCKS protein within U87 GBM
cells (Fig. 5A) showed a 52% decrease in proliferation rate compared to control (p=0.0003)
(Fig. 5B). We attempted to generate a stable overexpressing cell line, but we were unable to
do so as these cells did not increase in confluence over a period of 21 days, while the control
cell line was passaged three times during the same period. Because these cells did not
proliferate, the effect on radiation sensitivity due to MARCKS overexpression could not be
assessed.
We noted from imaging that the MARCKS overexpressing cells were adopting a flattened
morphology and had a 50-fold increase in size compared to the control cell line (p<0.0001)
(Fig. 5C, D, and E). These morphological changes are consistent with senescence, a state in
which normal diploid cells lose their ability to divide (35, 36). The MARCKSoverexpressing U87 cells were stained for SA-β-gal to confirm senescence (Fig. 5C and D).
The percent of cells staining positive for SA-β-gal was quantified and 41.5% of the
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MARCKS-overexpressing U87 demonstrated positive staining, while none of the control
cells stained positive (Fig. 5F)(p<0.0001). Because SA-β-gal is a relatively insensitive
marker of senescence, we also quantified the percent of cells demonstrating the morphologic
changes consistent with senescence. 200 cells were imaged and 79.5% of the MARCKSoverexpressing cells demonstrated these changes compared to 1% of the control cells. We
also noted the presence of multi-nucleated giant cells, which are morphologically similar to
those found in a previously identified giant cell GBM subtype (37) (central panel, Fig. 5D).
The multi-nucleated giant cells in giant cell GBM are halted in the early phases of mitosis
and lack proliferative capacity (38). These results confirm MARCKS as a regulator of GBM
growth and suggest a novel role in regulating senescence.
MARCKS Expression is a Favorable Prognostic Factor for Glioma Patients

NIH-PA Author Manuscript

In light of our cell culture and xenograft model data, we anticipated that overexpression of
MARCKS would be a favorable characteristic for survival. Thus we sought to evaluate
MARCKS expression more closely in terms of clinical outcomes. We thus analyzed
MARCKS gene expression in all glioma samples (low grade and high grade) within the
REMBRANDT database for survival probability. As shown in Fig. 6A, we compared the
survival of glioma patients with MARCKS expression above and below the median
expression and found a statistically significant survival benefit for those patients with high
MARCKS expression (HR = 0.55; 95% CI 0.43–0.69; p<0.001 by Cox model). This
suggested that up-regulation of MARCKS is a favorable prognostic factor for patients with
glioma.
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To confirm and expand the REMBRANDT data, we performed similar analyses using the
TCGA database that was used to define GBM molecular subtypes (6). We analyzed
MARCKS gene expression within the TCGA dataset of 192 GBM patients that had no prior
glioma with defined molecular subtype information. We fit a Cox proportional hazards
model as a function of age and MARCKS expression and discovered a protective influence
of increased MARCKS expression on survival outcome (p=0.044, Supplementary Table 2).
We also performed survival analyses for each subtype (Classical, Mesenchymal, Neural, and
Proneural) and found that only the Proneural subtype retained statistical significance when
age-adjusted (p=0.003594) (Supplementary Table 2). This analysis shows that the influence
of MARCKS expression on survival outcome shows high subtype specificity with very
strong effect in the Proneural subtype and almost no effect in the other subtypes, thus the
full sample analysis effectively shows a dilution of the effect in the Proneural subtype. To
observe the linearity of the effect of MARCKS gene expression on survival within Proneural
individuals, we performed survival regression in which we categorized MARCKS
expression by quartiles (4 levels), (Supplementary Table 2). The quartile-based analysis
shows the effect of MARCKS to be highly nonlinear, with the 4th quartile (highest
MARCKS expression) showing a strong protective influence compared with other quartiles
(HR=0.28, p=0.01). In further analysis, we chose to dichotomize MARCKS at the 4th
quartile for maximum discrimination (Median Survival of 47.2 months versus 12.2 months,
HR=0.21; 95% CI 0.09–0.48; p<0.0002) as shown in Fig. 6B.

MGMT methylation status and age are the two most common factors in determining
prognosis for GBM. We therefore performed survival analysis after adjusting for both
MGMT status and age using the MARCKS quartile expression data (Fig. 6C and
Supplementary Table 2). The MGMT term did not show significance (HR=1.48, p=0.24) as
a main effect, but we suspected a possible interaction with MARCKS. We then stratified by
MGMT status (methylated and unmethylated), and found that MARCKS protection was
highly significant in the unmethylated individuals (Median Survival of 65.3 months versus
10.7 months, HR=0.11; 95% CI 0.03–0.39; p<0.001), but not significant in the methylated
individuals (HR=0.39, p=0.19). This indicates that the patients that benefit to the highest
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degree from elevated MARCKS expression in GBM are those of the Proneural subtype with
unmethylated MGMT status.

NIH-PA Author Manuscript

DISCUSSION

NIH-PA Author Manuscript

Our analysis of survival outcomes in the REMBRANDT and TCGA databases with respect
to MARCKS expression in all samples indicated a direct correlation with patient survival
(Fig. 6A and B, Supplementary Table 2). However, we suspect that the importance of
MARCKS may ultimately depend on the particular cell signaling cascades that are active
within the tumor. This is consistent with our data showing molecular subtype specificity in
the TCGA analysis. Indeed, when we looked at MARCKS impact on survival based on
molecular subtype, only the Proneural subtype retained significance (Supplementary Table
2). An even more striking result is observed when MARCKS expression is broken down into
quartiles. Within the Proneural subtype, the highest quartile (4th quartile; highest MARCKS
levels) demonstrates a significant survival benefit compared to the lower 3 quartiles; with
50% of patients surviving three years or more (Fig. 6B). Surprisingly, the importance of
MARCKS was particularly evident in unmethylated MGMT tumors of the Proneural
subtype. Patients with unmethylated MGMT are expected to suffer from especially poor
outcomes. However, we noted that unmethylated MGMT tumors with high MARCKS
expression had a much better prognosis than those with low MARCKS expression (Fig. 6C).
Therefore, MARCKS expression has protective influence and prognostic value above and
beyond the two most commonly used predictive factors for survival, age and MGMT status
(HR=0.18, p=0.001) for those patients with GBM tumors of the Proneural subtype.
However, the mode of action may be complex, as the protective influence seems to interact
with MGMT status. Our results predict that individuals with unmethylated MGMT, which
are considered of poorer prognostic status due to their decreased sensitivity to therapy,
benefit to a much greater extent from higher MARCKS expression than their methylated
counterparts. To our knowledge, this is the first prognostic factor for individuals with tumors
with un-methylated MGMT that would outperform the methylated group in terms of
survival.
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Our results suggest that this survival benefit may be in part due to the MARCKS protein’s
ability to regulate proliferation and radiation sensitivity. This likely occurs through
modulation of PIP2-dependent signaling pathways such as cell division and the PI3K/Akt
pathway; as well as a potential role in regulating senescence. PI3K mutations are a common
occurrence in the Proneural subtype, and thus MARCKS expression would have a direct
impact on signaling through this pathway in these tumors (6). PDGFR mutations are also
frequent, and MARCKS expression could modulate this pathway by controlling the
availability of PIP2 to cleavage by Phospholipase C (PLC) or conversion to PIP3 by PI3K.
A link between MARCKS and other mutations such as IDH1 and TP53 that are
characteristic of this subtype is less clear.
It should be noted that MARCKS expression did not have an impact on survival in the
Classical subtype (Supplemental Table 2), for which EGFR mutations are relatively
common and aberrant phospholipid signaling would be expected. A potential explanation for
this might be the increased phosphorylation of MARCKS that was observed in EGFRvIII
expressing cells that showed changes in invasion (22). In these cells a greater proportion of
MARCKS is phosphorylated and thus unable to sequester PIP2 from participating in these
signaling cascades. In the context of this cellular background, high MARCKS expression
may have a reduced impact on modulating these pathways. It is also interesting that the U87
cell line enters a senescent state with over-expression of MARCKS, but U251 cells possess
high levels of MARCKS and continue to proliferate. Senescence is known to be dependent
on p53 and pRB DNA damage signaling pathways. U251 and U87 differ with respect to p53
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status (U251 is mutant, U87 is wild type)(39), so it is also likely that the differing cell
signaling backgrounds are responsible for this effect. This supports the concept that the
effect of high MARCKS expression on clinical outcome would be highly dependent on the
particular cell signaling background.
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Our results have also identified a potential novel role for the MARCKS protein in promoting
senescence and the formation of multi-nucleated giant cells. The large, flattened, multinucleated giant cells (central panel, Fig. 5D) found upon MARCKS over-expression are
morphologically similar to the giant cell GBM subtype (37). This giant cell subtype of GBM
strikes younger patients, has a better prognosis, and genetically resembles secondary disease
(i.e. high incidence of TP53 mutations and a low incidence of EGFR aberrations) (9, 40, 41),
similar to the recently identified Proneural subtype (6). It has been proposed that the
formation of these multi-nucleated giant cells is the product of abnormal centrosome
duplication resulting from the high incidence of TP53 mutations that is characteristic of the
giant cell GBM subtype (40, 41). As mentioned above, the wild-type p53 status of U87 cells
(39) suggests that high levels of the MARCKS protein may interfere with the function of the
p53 protein leading to the formation of multi-nucleated giant cells. However, the formation
of these cells may also be a result of the MARCKS protein’s role in regulating the actin
cytoskeleton, as it has been previously shown that experimental sequestration of PIP2 leads
to defects in cytokinesis and the formation of multi-nucleated cells (42, 43). We also noted
that these giant cells were in a senescent state, indicated by positive staining for SA-β-gal
(Fig. 5C and D). High levels of MARCKS have been previously associated with a quiescent
state in fibroblasts (44), however, to our knowledge this is the first report that the MARCKS
protein can induce a senescent state. The induction of such a state in GBM has obvious
clinical implications.
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To our surprise, the increases in PI3K/Akt signaling following MARCKS knockdown in
U251 were not mirrored by MARCKS over-expression in U87 as we found no
commensurate decrease in Akt activation. This is likely the result of changes in signaling
that occur with senescence. It has been previously shown that Akt activity increases with
adoption of the senescent state (45). Thus, any decreases in signaling through PI3K/Akt
from MARCK over-expression may be eliminated by a compensatory up-regulation of Akt
activity. These data suggest that alternative cell signaling pathways regulated by the
MARCKS protein should not be excluded and warrant further investigation. For example, as
a major substrate for PKC, higher levels of MARCKS might lead to decreased signaling
through alternate PKC substrates. As a binding partner for Ca2+-Calmodulin, higher levels
of MARCKS might lead to decreased signaling through alternate Calmodulin pathways.
Thus, the impact that MARCKS expression has on these cell signaling pathways, and
therefore patient survival, is likely due to a balance of the predominant cell signaling
pathways that are characteristic of that particular disease background. As such, our results
indicate that MARCKS is a novel biomarker and therapeutic target for a specific group of
GBM patients, particularly those with Proneural tumors with un-methylated MGMT
promoters. Efforts are currently underway to identify therapies that increase MARCKS
expression in the context of this cellular background, as this may provide a significant
survival benefit for these patients.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Glioblastoma multiforme (GBM) is the most common and deadly primary brain
malignancy necessitating improved understanding of GBM biology. In this study, we
explore the role of Myristoylated Alanine Rich C-Kinase Substrate (MARCKS) in the
context of GBM. We have discovered that the MARCKS protein regulates GBM growth
as well as response to radiation therapy through its effects on proliferation, senescence,
and DNA repair based on our studies in cell culture and in patient-derived xenograft
tumors implanted in mice. Importantly, our analysis of clinical patient data demonstrates
that MARCKS is an independent predictor for outcome in GBM patients. Indeed, high
MARCKS levels promoted improved outcomes, which was consistent across our model
systems. Our results suggest that MARCKS may be a biomarker for prognosis as well as
a potential target for therapy in GBM.
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Figure 1.

Several GBM cell lines were grown under standard growth conditions and total protein
lysates were prepared as described in the Methods and probed for MARCKS,
phosphorylated Akt on serine 473 (pAkt Ser473), total Akt, and GAPDH (for protein
normalization) by immunoblotting (A). Proliferation was determined for each cell line using
a WST-1 cell proliferation assay (Supplementary Fig. S1) as described in the Methods.
Densitometric quantitation of MARCKS levels were performed and normalized to GAPDH
and relative levels of MARCKS were plotted vs. proliferation (Mean OD) with R2
correlation (B). Human GBM xenografts were harvested from athymic nude mice and total
protein lysates were prepared as described in the Methods and probed for MARCKS,
phosphorylated Akt on serine 473 (pAkt Ser473), total Akt, and GAPDH (for protein
normalization) by immunoblotting (C). Densitometric quantitation of MARCKS levels were
performed and normalized to GAPDH and relative levels of MARCKS were plotted vs.
intracranial (IC) growth rate in days with R2 correlation (D).
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Figure 2.
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Parental U251 (WT=wild type) cells were infected with a control or MARCKS shRNA
knockdown (MARCKS) lentiviral vector and selected for antibiotic resistance as described
in Methods. The control and knockdown cell lines were probed for MARCKS,
phosphorylated Akt on serine 473 (pAkt Ser473), total Akt, and GAPDH (for protein
normalization) by immunoblotting (A). Proliferation was assessed using ATPlite
Luminescence Assay System with mean and standard error shown (** = p<0.01) (B).
Clonogenic survival assay was performed on U251 cells infected with either control or
MARCKS shRNA (Knockdown) lentiviral vector and plotted in a semi-logarithmic fashion
as mean surviving fraction (with standard error of the mean) vs. radiation dose in Gy (C).
An upward and rightward shift indicates radiation protection.
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Figure 3.

Quantification of γH2AX foci was performed at the indicated time points after 8 Gy
radiation (*** = p<0.001) (A). DNA repair by non-homologous end joining (NHEJ) was
assessed by immunoblotting for phosphorylated DNA-PK at the indicated time points after
treatment with 8 Gy (B). The distribution of the cell cycle at 8 hours and 24 hours after 8 Gy
was assessed by propidium iodide staining and flow cytometry. Representative histograms
for the control and MARCKS knockdown cell line at each time point are shown (C). Mean
values for each phase of the cell cycle at each time point and p values for control versus
MARCKS knockdown are available in Supplementary Fig. S3B and S3C.
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Figure 4.

Mitotic catastrophe was quantified at 24, 48, and 72 hours after 8 Gy radiation by DAPI
stain and counting the number of multi-nucleated cells per field (40×)(* = p<0.05)(A). An
example of mitotic catastrophe is available in Supplementary Fig. S4. Autophagy was
quantified at 72 hours after 8 Gy radiation by immunoblotting for conversion of LC3-I to
LC3-II with normalization to α-Tubulin (B). Apoptosis was quantified after 8 Gy radiation
by immunoblotting for cleaved caspase 3 at 12 and 24 hours (C), and by quantification of
pyknotic nuclei per field (40×) at 24, 48, and 72 hours (* = p<0.05)(D). An example of a
pyknotic nucleus is available in Supplementary Fig. S4.
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Figure 5.
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Parental U87 (WT=wild type) cells were infected with a control or MARCKS expression
(MARCKS) lentiviral vector and selected for antibiotic resistance as described in Methods.
The control and MARCKS overexpressing cell lines were probed for MARCKS,
phosphorylated Akt on serine 473 (pAkt Ser473), total Akt, and GAPDH (for protein
normalization) by immunoblotting (A). Proliferation was assessed using ATPlite
Luminescence Assay System with mean and standard error shown (*** = p<0.001)(B).
Representative photos showing phase contrast images of Control (C) or MARCKS overexpressing (D) cells at 20× magnification. The center image of the MARCKS overexpressing cells demonstrates a multi-nucleated cell. The blue color indicates positive
staining for Senescence associated β-galactosidase (SA-β-gal). Cell area of the MARCKS
over-expressing and control cell line was measured using ImageJ as described in the
Supplementary Methods and mean cell area with standard error of the mean is plotted (****
= p<0.0001)(E). Senescence was quantified by counting the percent of cells staining positive
for SA-β-gal at 10× magnification (**** = p<0.0001)(F).
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Figure 6.
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Kaplan-Meier curves for MARCKS expression above (Green) and below (red) the median in
all glioma samples from the REMBRANDT database (46) (A). National Cancer Institute.
2005. REMBRANDT home page. <http://rembrandt.nci.nih.gov>. Accessed 2011
September 30. Kaplan-Meier curves (age-adjusted) for MARCKS expression dichotomized
on the fourth quartile (4th Quartile=MHigh) vs. the lower three quartiles (1st – 3rd
Quartile=MLow) in Proneural GBM samples from the TCGA database (B) and then further
stratified by MGMT status (Meth=Methylated promoter; Unmeth=Unmethylated promoter)
(C) (47) The number at risk at indicated time points is shown below each curve.
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